Compare ALV & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALV | CYTK |
|---|---|---|
| Founded | 1953 | 1997 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.7B |
| IPO Year | 1997 | 2004 |
| Metric | ALV | CYTK |
|---|---|---|
| Price | $121.13 | $76.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $134.00 | $89.26 |
| AVG Volume (30 Days) | 729.9K | ★ 1.7M |
| Earning Date | 04-17-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $10,815,000,000.00 | $13,368,000.00 |
| Revenue This Year | $2.10 | $7.37 |
| Revenue Next Year | $3.47 | $310.19 |
| P/E Ratio | $37.77 | ★ N/A |
| Revenue Growth | ★ 4.09 | N/A |
| 52 Week Low | $99.16 | $35.22 |
| 52 Week High | $132.17 | $88.31 |
| Indicator | ALV | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 42.42 |
| Support Level | $113.89 | $73.95 |
| Resistance Level | $124.61 | $79.66 |
| Average True Range (ATR) | 2.82 | 2.88 |
| MACD | -0.07 | -0.47 |
| Stochastic Oscillator | 47.33 | 15.31 |
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.